Purchase this article with an account.
Reuben Chao Ming Foo, Ecosse L. Lamoureux, Ryan C. K. Wong, Sue-Wei Ho, Peggy P. C. Chiang, Gwyneth Rees, Tin Aung, Tina T. Wong; Acceptance, Attitudes, and Beliefs of Singaporean Chinese Toward an Ocular Implant for Glaucoma Drug Delivery. Invest. Ophthalmol. Vis. Sci. 2012;53(13):8240-8245. doi: 10.1167/iovs.12-10393.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
We investigated patients' attitudes and perceptions toward a subconjunctival implant as a novel ocular drug delivery method for glaucoma.
We recruited 344 Chinese patients with primary open angle or angle closure glaucoma currently on topical antiglaucoma medication for a minimum of six months from specialist glaucoma clinics. Sociodemographic data, and information about patients' general and ocular health were collected. Beliefs about medicines, glaucoma, eye drops, and self-reported adherence were assessed by trained interviewers using validated questionnaires. A description about the implant was provided and patients subsequently were assessed on their understanding and acceptance.
Of the 344 Chinese patients enrolled, 216 (62.8%) would accept the implant as a replacement for their current eye drops. Of those who accepted the implant, 99 (45.8%) were willing to accept it at similar costs, while 40 (18.5%) and 20 (9.3%) patients were willing to pay 1.5 and 2 times the cost of their present medication, respectively. Patients who accepted the implant had more severe glaucoma (P = 0.015) and felt that the implant was more helpful than eye drops (P < 0.001). Beliefs toward medicines, glaucoma, eye drops, self-reported adherence, and sociodemographic factors did not have a significant impact on the patients' decisions.
An ocular drug implant would be an acceptable alternative to topical eye drops for subgroups of glaucoma patients.
This PDF is available to Subscribers Only